Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know

What Happened?

A number of stocks jumped in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. 

The proposal would extend subsidies set to expire at the end of the year, with new eligibility limits for individuals with incomes up to 700% of the federal poverty line. These subsidies, a key part of the Affordable Care Act (ACA), help lower the cost of health insurance for consumers, making them crucial for insurers focused on the ACA marketplace. An extension would likely support sustained enrollment, securing a key revenue stream for these companies.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Surgical Equipment & Consumables - Specialty company Integra LifeSciences (NASDAQ:IART) jumped 3%. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it’s free for active Edge members.
• Healthcare Technology for Providers company Evolent Health (NYSE:EVH) jumped 8.6%. Is now the time to buy Evolent Health? Access our full analysis report here, it’s free for active Edge members.
• Immuno-Oncology company Incyte (NASDAQ:INCY) jumped 4%. Is now the time to buy Incyte? Access our full analysis report here, it’s free for active Edge members.
• Patient Monitoring company iRhythm (NASDAQ:IRTC) jumped 2.8%. Is now the time to buy iRhythm? Access our full analysis report here, it’s free for active Edge members.
• Health Insurance Providers company Clover Health (NASDAQ:CLOV) jumped 5.5%. Is now the time to buy Clover Health? Access our full analysis report here, it’s free for active Edge members.

Zooming In On Evolent Health (EVH)

Evolent Health’s shares are extremely volatile and have had 45 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 3 days ago when the stock gained 13.2% on the news that comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.

Evolent Health is down 61.1% since the beginning of the year, and at $4.47 per share, it is trading 66.3% below its 52-week high of $13.26 from November 2024. Investors who bought $1,000 worth of Evolent Health’s shares 5 years ago would now be looking at an investment worth $302.30.

Microsoft, Alphabet, Coca-Cola, Monster Beverage—all began as under-the-radar growth stories riding a massive trend. We’ve identified the next one: a profitable AI semiconductor play Wall Street is still overlooking.Go here for access to our full report.